| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD25 |
| Clinical data | |
| Trade names | Zinbryta (multiple sclerosis) Zenapax (acute transplant rejection, discontinued in 2009) |
| AHFS/Drugs.com | zinbryta |
| Pregnancy category |
|
| Routes of administration | Subcutaneous injection, Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 90% |
| Metabolism | Proteases |
| Elimination half-life | 21 days (11–38 days) |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C6332H9808N1678O1989S42 |
| Molar mass | 142612.39 g·mol−1 |
  (what is this?) (verify) | |
Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.
In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe.[4][5][3]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.
- ^ a b "FDA working with manufacturers to withdraw Zinbryta from the market in the United States". U.S. Food and Drug Administration (FDA). Retrieved 15 March 2018.
- ^ "Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta". Reuters. 2018.
- ^ Loftus P (2 March 2018). "Biogen and Abbvie Take Multiple Sclerosis Drug Off Market". The Wall Street Journal.